Pfizer (PFE) is a publicly traded Healthcare sector company. As of May 20, 2026, PFE trades at $25.78 with a market cap of $144.37B and a P/E ratio of 19.70. PFE moved +0.47% today. Year to date, PFE is +1.91%; over the trailing twelve months it is +11.57%. Its 52-week range spans $20.92 to $30.43. Analyst consensus is neutral with an average price target of $29.17. Rallies surfaces PFE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Pfizer Advances 25-Valent Vaccine with up to 15x Stronger Immune Response: Pfizer's 25-valent pneumococcal vaccine candidate achieved 8.8 to 15 times higher immune response against serotype 3 compared with PREVNAR 20 in Phase 2 trials. It is advancing to a Phase 3 pediatric trial with 2,400 participants and aims to start a 35-valent adult candidate by end 2026.
| Metric | Value |
|---|---|
| Price | $25.78 |
| Market Cap | $144.37B |
| P/E Ratio | 19.70 |
| EPS | $1.31 |
| Dividend Yield | 0.43% |
| 52-Week High | $30.43 |
| 52-Week Low | $20.92 |
| Volume | 29.35M |
| Avg Volume | 0 |
| Revenue (TTM) | $63.31B |
| Net Income | $7.53B |
| Gross Margin | 73.51% |
22 analysts cover PFE: 0 strong buy, 8 buy, 11 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $29.17.